

Resource Summary Report

Generated by NIF on Aug 30, 2026

Bridging Interventional Development Gaps

RRID:SCR_005635

Type: Tool

Proper Citation

Bridging Interventional Development Gaps (RRID:SCR_005635)

Resource Information

URL: <http://www.ncats.nih.gov/research/reengineering/bridgs/bridgs.html>

Proper Citation: Bridging Interventional Development Gaps (RRID:SCR_005635)

Description: on a competitive basis, successful applicants receive access to NIH contractors who conduct preclinical studies at no cost to the investigator for the development of new therapeutic agents. In general, synthesis, formulation, pharmacokinetic and toxicology services in support of investigator-held Investigational New Drug (IND) applications to the Food and Drug Administration are available. Contract costs are supported by the NIH Common Fund and collaborating NIH Institutes and Centers. Access to contracts is based upon a peer-reviewed application process. The number of awards made will depend on the number of applications received, their scientific merit, and the availability of NIH funds. BrIDGs is not a complete drug development program or an unconditional commitment to develop a particular compound for the clinic. In some cases the program supports one or two key steps for preclinical development, while in other cases it assists with most of the development tasks needed to file an IND. The services provided by the program depend upon the stage of a given project and need for additional data. Once a project is approved, NIH staff work with principal investigators to develop a plan for the conduct of proposed studies. Contractors perform tasks approved by BrIDGs under the direction of NIH staff. Development proceeds sequentially in most cases and the start of one segment of the project (e.g., toxicology) may depend on satisfactory completion of preceding segments (e.g., formulation). Insurmountable difficulties in one segment may force the discontinuation of an entire project. BrIDGs supports projects proposed by academic institutions, not-for-profit organizations, and SBIR-eligible businesses. Foreign academic and non-profit institutions may also apply. Potential therapies for any disease or disorder may be submitted to BrIDGs. All proposed therapeutic agents should have demonstrated pharmacological activity in an appropriate in vivo disease model before applying.

Abbreviations: BrIDGs, RAID, NIH RAID

Synonyms: NIH Rapid Access to Intervention Development, Rapid Access to Intervention Development

Resource Type: analysis service resource, material analysis service, production service resource, service resource

Funding: NIH Common Fund

Resource Name: Bridging Interventional Development Gaps

Resource ID: SCR_005635

Alternate IDs: nlx_146247

Record Creation Time: 20220129T080231+0000

Record Last Update: 20260829T182943+0000

Ratings and Alerts

No rating or validation information has been found for Bridging Interventional Development Gaps.

No alerts have been found for Bridging Interventional Development Gaps.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We have not found any literature mentions for this resource.